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The neurotoxin I-methyl-4-phenyl-1,2,3,6_tetrahydropyridine (MPTP) and its deuterated analogues were 
oxidized to their corresponding dihydropyridinium species (MPDP+) by preparations of pure human liver 
MAO B:monoclonal antibody complex to investigate the mechanism of MPTP activation. Lineweaver- 
Burk plots of initial reaction rates revealed that the K,,,,app values for the various deuterated MPTP analogues 
were similar to those of MPTP. In contrast, V,,,~.,app values were substantially decreased by substitution of 
deuterium for hydrogen on the tetrahydropyridinium ring, especially at C-6. Deuterium substitution on the 
N-methyl group alone did not significantly reduce Vma..app. These studies support the interpretation that oxi- 
dation of MPTP at the C-4 position on the tetrahydropyridine ring is a major rate-determining step in its 
biotransformation by MAO B. 
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1. INTRODUCTION 
Several ines of evidence have shown that activa- 
tion of 1 -methyl-Cphenyl- 1,2,3 ,dtetrahydropyri- 
dine (MPTP) by mono~ine oxidase B (EC 
1.4.3.4) (MAO B) is a crucial step in generating 
neurotoxicity in mammals [l--5]. Oxidation of 
MPTP by MAO B has been demonstrated in a 
variety of species and tissues [1,4,6-g], and the 
enzyme-catalyzed formation of MPDP+ has been 
established [6,9]. However, the specific rate- 
determining step in this process remains unknown. 
For example, one or more uncharged species of 
MPDP could be formed initially, followed by 
isomerization to MPDP+. In an attempt o address 
this issue, we have synthesized 4 deuterated com- 
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pounds of MPTP and compared their initial rates 
of oxidation by purified human liver MAO B with 
MPTP. 
2. MATERIALS AND METHODS 
All MPTP deuterated analogues were synthe- 
sized according to [lo]. Melting points were deter- 
mined on a Fisher-Johns apparatus and are cor- 
rected. Electron impact mass spectra (EIMS) were 
obtained on a VG-Micromass 7070 F spectrometer 
with a DS 2050 data system. 4-Phenylpyridine, 
sodium borodeuteride-& (98% D) and methyl 
alcohol-d (99.5% D) were purchased from 
Aldrich. 
MPTP is readily obtained from 4-phenyl- 
pyridine (1) by quaternization with methyl iodide 
to methoiodide 2, and reduction of the latter with 
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sodium borohydride in methanol [IO]. Reduction 
of MPDP+ (4) with sodium borohydride also 
yields MPTP [S]. The deuterated analogues of 
MPTP shown in scheme 1 were obtained using 
trideuteromethyl iodide as the quaternizing agent 
and sodium borodeuteride for reduction. Reduc- 
tion of 2 with sodium borodeuteride gave 
2,3,6_trideuterated compound 5 (HCI salt, m.p. 
257°C; MS, m/e 176). Quaternization of 1 with 
trideuteromethyl iodide gave quaternary meth- 
oiodide 3 (m.p. 167-168”C), which was reduced 
with sodium borohydride to tetrahydropyridine 7 
deuterated in the methyl group (HCl salt, m.p. 
257’C; MS, m/e 176), and with sodium 
borodeuteride to hexadeutero compound 6 (HCl 
salt, m.p. 257-258°C; MS, m/e 179). Reduction 
of 4 with sodium borodeuteride in methanol af- 
forded 6-deutero-MPTP 8 (HCI salt; m.p. 
25%256”C, MS, m/e 174). 
Human liver MAO B was prepared using a 
monoclonal antibody (MAO B-lC2) specific for 
the B form of the enzyme [I 1,121 according to 
Pate1 et al. [13]. The enzyme-antibody complex, 
which is catalytically active, was assayed at 30°C 
using various concentrations of test compounds in 
0.5 ml of 25 mM sodium phosphate, pH 7.4. 
MPTP and its deuterated analogues were dissolved 
in buffer and their concentrations determined by 
measuring the absorbance at 243 nm of diluted 
stock solutions using a molar extinction coefficient 
of 1.30 x 104. Initial reaction rates were measured 
during the first 5 min by monitoring the increase in 
absorbance at 340 nm for the formation of the ap- 
propriate dihydropyridinium species using a 
Beckman DU7U spectrophotometer. MPDP+ has 
SCHEME I 
a molar extinction coefficient of 1.30 X lo4 in 
25 mM sodium phosphate buffer, pH 7.4. 
3. RESULTS 
The kinetic parameters obtained from 
Lineweaver-Burk plots for the oxidation of MPTP 
and its deuterated analogues to the dihydro- 
pyridinium species by pure human liver MAO 
B : MAO B- lC2 are shown in table 1. Values ob- 
tained for K,,,,app of MPTP and its deuterated 
analogues were similar, indicating that deuterium 
labeling did not alter the apparent affinity of the 
enzyme for these analogues. In contrast, com- 
pounds containing deuterium substitutions on the 
Table 1 
Kinetic parameters of MPTP and its deuterated 
analogues by pure human liver MAO B : MAO B-l C2 
from two individuals 
Compound K m.wp 
WI 
V max,app 
(nmol . min-’ . mg-‘) 
MPTP 65.8, 75.9 99.6, 84.0 
5 67.1, 82.0 60.1, 46.4 
6 71.1, 96.9 58.3, 44.6 
7 50.7, 69.7 90.8, 71.7 
8 59.2, 85.3 67.1, 55.9 
Human liver MAO B: MAO B-lC2, prepared from two 
individuals, was assayed spectrophotometrically by 
measuring the increase in absorbance at 340 nm with 6 
different concentrations of MPTP or its deuterated 
analogues (SO-333 PM). Values for K,,,.app and V,,,ax,app 
were obtained by linear regression analysis of l/V vs 
l/[S]. Reactions were carried out in 0.5 ml of 25 mM 
sodium phosphate buffer, pH 7.4, with either 18.2~g 
enzyme (preparation 1, left column) of 12.6 pg enzyme 
(preparation 2, right column) at 30°C and started by the 
addition of substrate. Initial rates were obtained with 
duplicate or triplicate determinations for each 
concentration from 0 to 5 min by monitoring the 
absorbance at 340 nm using a Beckman DU7U 
spectrophotometer. Correlation coefficients (~0.99) 
were obtained for all plots. It should be noted that liver 
MAO B from these individuals gave Km,app values of 
65.8 and 75.9,uM, respectively, for MPTP. Previous 
studies [6] with a different preparation gave a Kmvapp of 
316/M, a result which indicates that significantly 
different enzyme affinities for substrate may occur 
among individuals 
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tetrahydropyridine ring displayed significant 
reductions in the ~,,,ax,app compared to MPTP. 
Reduction (approx. 33%) of the I’,,,ax,app of MPTP 
was observed when the deutero label was restricted 
to the 6 position of the tetrahydropyridine ring (8). 
Further deuterium substitutions on the tetrahydro- 
pyridine ring (5) and on the ring and methyl group 
(6) resulted in only slightly additional decreases in 
the Vmax,app compared to 8. Little or no reduction 
of ~Inax.app was observed with methyl deuterated 
compound (7). 
4. DISCUSSION 
MAO B catalyzes the oxidative deamination of 
neuroactive and vasoactive amines in the central 
nervous system and peripheral tissues. Studies on 
the mechanism of enzyme action indicate that 
primary amines are first oxidized to imines, which 
are then hydrolyzed to their corresponding 
aldehydes and ammonia [14]. However, MPTP is 
a tertiary cyclic amine, and the mechanism of its 
oxidation is different. Increase of the absorption 
to 340 nm indicates that the tertiary amine, 
MPTP, is oxidized to the iminium salt, MPDP+. 
The oxidation of the deuterated forms of MPTP 
shows differential effects on Vmax,app whereas no 
apparent effect on the K,,,,app was observed. The 
fact that the K,,,,app was not significantly altered in- 
dicates that the affinity of MAO B for the 
deuterated substrates was unaffected. The reduc- 
tion in the Vmax,app for those compounds contain- 
ing the deutero label on the tetrahydropyridine 
ring, i.e. 5, 6, and 8, however, is indicative of a 
deuterium effect. Only 7, with the deutero label on 
the methyl group, was oxidized to the same extent 
as MPTP. The reduction of the V,,,ax,app for 8 was 
about the same as that of 5 and 6. Our results sup- 
port the interpretation that oxidation of MPTP at 
the C-6 position of the tetrahydropyridine ring is a 
rate-limiting step in the formation of MPDP+. 
Subsequent rearrangement of MPDP+ to un- 
charged isomers, which are highly labile, could 
occur. 
Previous studies have shown that MPDP+ is not 
a substrate for MAO B, but undergoes chemical 
disproportionation to MPTP and MPP+ [6,9]. 
This charged pyridinium species can compete for 
the uptake of dopamine in striatal synaptosomal 
102 
preparations [ 15,161. Furthermore, following in 
vivo administration of MPTP, MPP+ accumulates 
in neurons in the substantia nigra and is thought to 
be correlated with cytotoxicity [3,17]. 
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